Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
📈 **POSITIVE** • High confidence analysis (94%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business